Drug intelligence / Profile preview

GT-220F

Development stage: Phase 1
Lead developer: Geode Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

GT-220F is an orally administered investigational drug being developed by Geode Therapeutics for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is currently in Phase 1 clinical trials to evaluate its safety, tolerability, and optimal dosing in patients with mCRPC. The specific mechanism of action has not been disclosed publicly as of April 2025[1][2][3][7].

Beyond the preview

Go deeper on GT-220F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT-220F.

Explore the full profile